Role of E-Cadherin in Peritoneal Implantation and Metastasis of Ovarian Cancer

doi:10.12280/gjfckx.20230884

Abstract

Abstract:

Ovarian cancer is one of the important causes of cancer death in women, and the main reason for its poor prognosis is that ovarian cancer is prone to recurrence and metastasis in a short period of time. Metastasis of ovarian cancer involves many aspects, such as intercellular junction, angiogenesis, tumor microenvironment and so on. It has been found that epithelial cadherin (E-cadherin) is an important factor in the metastasis of ovarian cancer, which can participate in the metastasis of ovarian cancer by changing cell-cell adhesion, promoting angiogenesis, regulating the process of epithelial-mesenchymal transition, and promoting tumor invasion and infiltration. The structure and expression of E-cadherin in ovarian cancer will be described in detail, and the implantation and metastasis mechanism of ovarian cancer and the role of E-cadherin in ovarian cancer metastasis are reviewed, in order to provide new ideas for recurrence monitoring and follow-up treatment of ovarian cancer.

Key words: Cadherins, Ovarian neoplasms, Carcinoma, ovarian epithelial, Neoplasm metastasis, Epithelial-mesenchymal transition

QI Qi, GAO Ya-ting, XU Fei-xu. Role of E-Cadherin in Peritoneal Implantation and Metastasis of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2024, 51(2): 210-214.

References 36

[1]	Huang Y, Li C, Zhang X, et al. Nanotechnology-integrated ovarian cancer metastasis therapy: Insights from the metastatic mechanisms into administration routes and therapy strategies[J]. Int J Pharm, 2023, 636:122827. doi: 10.1016/j.ijpharm.2023.122827.
[2]	Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer[J]. BMJ, 2020, 371:m3773. doi: 10.1136/bmj.m3773.
[3]	Assidi M, Jafri MA, Abu-Elmagd M, et al. Prognostic value of E-Cadherin and its tumor suppressor role in Saudi women with advanced epithelial ovarian cancer[J]. Libyan J Med, 2021, 16(1):1994741. doi: 10.1080/19932820.2021.1994741.
[4]	Kielbik M, Szulc-Kielbik I, Klink M. E-Cadherin Expression in Relation to Clinicopathological Parameters and Survival of Patients with Epithelial Ovarian Cancer[J]. Int J Mol Sci, 2022, 23(22):14383. doi: 10.3390/ijms232214383.
[5]	Sisto M, Ribatti D, Lisi S. E-Cadherin Signaling in Salivary Gland Development and Autoimmunity[J]. J Clin Med, 2022, 11(8):2241. doi: 10.3390/jcm11082241.
[6]	Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer[J]. Oncogene, 2018, 37(35):4769-4780. doi:10.1038/s41388-018-0304-2. pmid: 29780167
[7]	Kaszak I, Witkowska-Piłaszewicz O, Niewiadomska Z, et al. Role of Cadherins in Cancer-A Review[J]. Int J Mol Sci, 2020, 21(20):7624. doi: 10.3390/ijms21207624.
[8]	Rubtsova SN, Zhitnyak IY, Gloushankova NA. Dual role of E-cadherin in cancer cells[J]. Tissue Barriers, 2022, 10(4):2005420. doi: 10.1080/21688370.2021.2005420.
[9]	Rosso M, Majem B, Devis L, et al. E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness[J]. PLoS One, 2017, 12(9):e0184439. doi: 10.1371/journal.pone.0184439.
[10]	Henri JL, Macdonald J, Strom M, et al. Aptamers as potential therapeutic agents for ovarian cancer[J]. Biochimie, 2018, 145:34-44. doi: 10.1016/j.biochi.2017.12.001. pmid: 29224849
[11]	徐鸿斌. 磁共振弥散加权成像联合血清血管内皮生长因子、基质金属蛋白酶抑制剂-1、基质金属蛋白酶-9检测对卵巢癌腹膜转移的诊断价值[J]. 中国性科学, 2021, 30(6):74-76. doi: 10.3969/j.issn.1672-1993.2021.06.023.
[12]	Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis[J]. Trends Cell Biol, 2019, 29(3):212-226. doi: 10.1016/j.tcb.2018.12.001. pmid: 30594349
[13]	Liu C, Yu M, Li Y, et al. Lidocaine inhibits the metastatic potential of ovarian cancer by blocking Na_V 1.5-mediated EMT and FAK/Paxillin signaling pathway[J]. Cancer Med, 2021, 10(1):337-349. doi: 10.1002/cam4.3621.
[14]	Xie W, Yu J, Yin Y, et al. OCT4 induces EMT and promotes ovarian cancer progression by regulating the PI3K/AKT/mTOR pathway[J]. Front Oncol, 2022, 12:876257. doi: 10.3389/fonc.2022.876257.
[15]	Loh CY, Chai JY, Tang TF, et al. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges[J]. Cells, 2019, 8(10):1118. doi: 10.3390/cells8101118.
[16]	金福军. 上皮性卵巢癌腹腔转移机制及治疗的研究进展[J]. 重庆医学, 2022, 51(12):2140-2144. doi: 10.3969/j.issn.1671-8348.2022.12.034.
[17]	Zhao C, She X, Zhang Y, et al. LRRC4 Suppresses E-Cadherin-Dependent Collective Cell Invasion and Metastasis in Epithelial Ovarian Cancer[J]. Front Oncol, 2020, 10:144. doi: 10.3389/fonc.2020.00144. pmid: 32117780
[18]	Pascual-Antón L, Cardeñes B, Sainz de la Cuesta R, et al. Mesothelial-to-Mesenchymal Transition and Exosomes in Peritoneal Metastasis of Ovarian Cancer[J]. Int J Mol Sci, 2021, 22(21):11496. doi: 10.3390/ijms222111496.
[19]	Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis[J]. J Hematol Oncol, 2022, 15(1):129. doi: 10.1186/s13045-022-01347-8.
[20]	Roque R, Costa Sousa F, Figueiredo-Dias M. Epithelial-mesenchymal interconversions in ovarian cancer: The levels and functions of E-cadherin in intraabdominal dissemination[J]. Oncol Rev, 2020, 14(2):475. doi: 10.4081/oncol.2020.475. pmid: 32676171
[21]	Závesk L, Jandáková E, Weinberger V, et al. Ascites in ovarian cancer: MicroRNA deregulations and their potential roles in ovarian carcinogenesis[J]. Cancer Biomark, 2022, 33(1):1-16. doi: 10.3233/CBM-210219.
[22]	Gunay G, Kirit HA, Kamatar A, et al. The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration[J]. Gynecol Oncol, 2020, 159(2):563-572. doi: 10.1016/j.ygyno.2020.09.002. pmid: 32958270
[23]	Burleson KM, Casey RC, Skubitz KM, et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers[J]. Gynecol Oncol, 2004, 93(1):170-181. doi: 10.1016/j.ygyno.2003.12.034. pmid: 15047232
[24]	Gogola-Mruk J, Tworzydło W, Krawczyk K, et al. Visfatin induces ovarian cancer resistance to anoikis by regulating mitochondrial activity[J]. Endocrine, 2023, 80(2):448-458. doi: 10.1007/s12020-023-03305-x. pmid: 36658296
[25]	Momen Razmgah M, Ghahremanloo A, Javid H, et al. The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells[J]. Mol Biol Rep, 2022, 49(10):9307-9314. doi: 10.1007/s11033-022-07771-w. pmid: 35960409
[26]	Stieg DC, Wang Y, Liu LZ, et al. ROS and miRNA Dysregulation in Ovarian Cancer Development, Angiogenesis and Therapeutic Resistance[J]. Int J Mol Sci, 2022, 23(12):6702. doi: 10.3390/ijms23126702.
[27]	Wu C, Cipollone J, Maines-Bandiera S, et al. The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression[J]. Differentiation, 2008, 76(2):193-205. doi: 10.1111/j.1432-0436.2007.00193.x. pmid: 17608733
[28]	Sawada K, Mitra AK, Radjabi AR, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target[J]. Cancer Res, 2008, 68(7):2329-2339. doi: 10.1158/0008-5472.CAN-07-5167. pmid: 18381440
[29]	Cai S, Zhang P, Dong S, et al. Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells[J]. Cell Physiol Biochem, 2018, 45(3):1061-1071. doi: 10.1159/000487348. pmid: 29439245
[30]	Yousefi M, Dehghani S, Nosrati R, et al. Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles[J]. Cell Oncol(Dordr), 2020, 43(4):515-538. doi: 10.1007/s13402-020-00513-9.
[31]	Iyoshi S, Yoshihara M, Nakamura K, et al. Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer[J]. Int J Cancer, 2021, 149(11):1961-1972. doi: 10.1002/ijc.33770. pmid: 34469585
[32]	Siu M, Jiang YX, Wang JJ, et al. PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8 signaling[J]. Oncogenesis, 2020, 9(2):24. doi: 10.1038/s41389-020-0209-0.
[33]	Tang M, Yue P, Ip PP, et al. Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface[J]. Nat Commun, 2018, 9(1):2270. doi: 10.1038/s41467-018-04695-7. pmid: 29891938
[34]	Tang M, Ip PP, Wong A. New insights into the role of soluble E-cadherin in tumor angiogenesis[J]. Cell Stress, 2018, 2(9):236-238. doi: 10.15698/cst2018.09.154. pmid: 31225492
[35]	Han Y, Song C, Zhang T, et al. Wilms′ tumor 1 (WT1) promotes ovarian cancer progression by regulating E-cadherin and ERK1/2 signaling[J]. Cell Cycle, 2020, 19(20):2662-2675. doi: 10.1080/15384101.2020.1817666.
[36]	Wei L, He Y, Bi S, et al. miRNA-199b-3p suppresses growth and progression of ovarian cancer via the CHK1/E-cadherin/EMT signaling pathway by targeting ZEB1[J]. Oncol Rep, 2021, 45(2):569-581. doi: 10.3892/or.2020.7895.